As per the agreement, Dimerix is expected to use its GPCR-HIT platform and insights into the ability of G-Protein Coupled Receptors (GPCRs) to form complexes, called heteromers, to work with undisclosed GPCRs of interest to Takeda.
Tim Grogan, CEO of Dimerix, said: “Dimerix’ GPCR-HIT platform enables the development of more specific drugs that take into account the signaling profile of GPCRs acting in heteromeric complexes. We are very pleased to be working with Takeda to apply our GPCR-HIT technology. Our interactions with Takeda have been very impressive.”
Mark Carlton, president of Takeda Cambridge, said: “We are pleased to enter into this agreement to apply Dimerix’ GPCR-HIT platform. This work will continue to build on our knowledge of key GPCRs, which are drug targets of major significance.”
Dimerix Bioscience is a pre-clinical stage product company developing a pipeline of lead products with specific activity and with reduced risk of off-target effects.